)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lipigon Pharmaceuticals
Lipigon Pharmaceuticals (LPGO) investor relations material
Lipigon Pharmaceuticals has been delisted
Lipigon Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Topline data from the phase II study of Lipisense® showed good safety but no clinically relevant reduction in triglycerides or remnant cholesterol; a trend toward improved insulin resistance was observed.
A strategic review was initiated, and cost-saving measures were implemented to reduce the cost base by about 65%.
The company is evaluating strategic alternatives, including partnerships and new indications, due to limited liquidity and the need for additional financing.
Financial highlights
Net sales for Jan–Dec 2025 were 0 tkr, down from 10,287 tkr in the previous year.
Operating loss for Jan–Dec 2025 was -32,218 tkr, compared to -25,576 tkr year-over-year.
Cash and cash equivalents at year-end were 10,214 tkr, down from 11,775 tkr.
Equity at year-end was 7,912 tkr, with an equity per share of 0.01 kr.
Soliditet (equity ratio) improved to 68.9% from 52.4% year-over-year.
Outlook and guidance
The company lacks sufficient working capital for the next twelve months and requires new financing to continue operations.
If the ongoing strategic review does not yield satisfactory results, bankruptcy may be considered.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lipigon Pharmaceuticals
- Lipisense® showed safety but no significant lipid-lowering effect in Phase II trial.LPGO
Study Result - Phase II Lipisense® study nears data readout; financing secured but future depends on results.LPGOQ3 2025
- Phase II Lipisense® trial completed enrollment; rights issue boosts liquidity amid ongoing losses.LPGOQ2 2025
- Operating loss widened as clinical costs rose, but Lipisense® milestone payment boosts outlook.LPGOQ3 2024
- Milestone payments and warrant exercises boost Lipigon's cash as Lipisense® clinical work advances.LPGOQ2 2024
- Lipigon secured SEK 37.4m in new funding to advance Lipisense® clinical development.LPGOQ1 2025
- Net loss widened in 2024, but new funding and positive Lipisense® data support future progress.LPGOQ4 2024
Lipigon Pharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lipigon Pharmaceuticals AB specializes in developing therapeutics for lipid-related disorders. The company focuses on creating drugs with unique mechanisms of action to treat diseases resulting from disruptions in the body's lipid metabolism. Their projects include treatments for severe hypertriglyceridemia, familial chylomicronemia syndrome, lipodystrophy, dyslipidemia, and acute respiratory distress syndrome. The company is headquartered in Umeå, Sweden, and its shares are listed on the OMX Stockholm.